Cell cycle models for molecular biology and molecular oncology: Exploring new dimensions

Cytometry

Volumn 35, Issue 2, 1999, Pages 97-116

  Shackney, Stanley E ^a   Shankey, T Vincent ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cell cycle; Models; Neoplastic transformation; Oncogenes; Signal transduction

Indexed keywords

ARTICLE; CELL CYCLE; CELL PROLIFERATION; MALIGNANT TRANSFORMATION; MITOSIS; MOLECULAR BIOLOGY; MOLECULAR MODEL; ONCOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; EVOLUTION, MOLECULAR; FLOW CYTOMETRY; HUMANS; MODELS, BIOLOGICAL; MOLECULAR BIOLOGY; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033081905     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.0.CO;2-5     Document Type: Article

References (130)

1. Smith J, Martin L. Do cells cycle? Proc Natl Acad Sci USA 1973:70: 1263-1267.
2. Pardee A. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974;71:1286-1290.
3. 1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163.
4. Hunter T, Pines J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
5. Pardee A. Principles of cancer biology: biochemistry and cell biology. In: DeVita VJ, Hellman S, Rosenberg S. editors. Cancer principles and practice of oncology. Philadelphia: J.B. Lippincott; 1985. p 3-16.
6. Baisch H, Otto U, Hatje U, Fack H. Heterogeneous cell kinetics in tumors analyzed with a simulation model for bromodeoxyuridine single and multiple labeling. Cytometry 1995;21:52-61.
7. Shackney S. A cytokinetic model for heterogeneous mammalian cell populations. I. Cell growth and cell death. J Theor Biol 1973;38:305-333.
8. Baisch H, Otto U. Intratumoral heterogeneity of S phase transition in solid tumours determined by bromodeoxyuridine labelling and flow cytometry. Cell Prolif 1993;26:439-448.
9. Juan G, Li X, Darzynkiewicz Z. Correlation between DNA replication and expression of cyclins A and B1 in individual MOLT4 cells. Cancer Res 1997;57:803-807.
10. Cheng H, Leblond C. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. 1. Columnar cell. Am J Anat 1974;141:461-480.
11. Quastler H, Sherman F. Cell population kinetics in the intestinal epithelium of the mouse. Exp Cell Res 1959;17:420-438.
12. Weinstein G, Van Scott E. Autoradiographic analysis of turnover times of normal and psoriatic epidermis. J Invest Dermatol 1965;45: 257-262.
13. Shackney S, Ford S, Wittig A. Kinetic-microarchitectural correlations in the bone marrow of the mouse. Cell Tissue Kinet 1975;8:505-516.
14. Grisham J. Cellular proliferation in the liver. In: Fry R, Griem M, Kirsten W, editors. Normal and malignant cell growth. New York: Springer-Verlag; 1969. p 28-42.
15. Morris R, Potten C. Slowly cycling (label-retaining) epidermal cells behave like clonogenic stem cells in vitro. Cell Prolif 1994;27:279-289.
16. Lord B, Hendry J. The distribution of haemopoietic colony-forming units in the mouse femur, and its modification by X-rays. Br J Radiol 1972;45:110-115.
17. Tannock I. Biology and tumor growth. Hosp Pract 1983;18:81-93.
18. McCulloch E, Till J. Proliferation of hemopoietic colony-forming cells transplanted into irradiated mice. Radiat Res 1964;22:383-397.
19. Laird A. Dynamics of growth in tumors and in normal organisms. In: Perry S, editor. National Cancer Institute monographs: human tumor cell kinetics. Washington, DC: U.S. Government Printing Office: 1969. p 15-28.
20. Schabel F Jr. Concepts for treatment of micrometastases developed in murine systems. Am J Roentgenol Radium Ther Nucl Med 1976;126:500-511.
21. Shackney S, McCormack G, Cuchural G Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy Ann Intern Med 1978;89:107-121.
22. Shackney S. A cytokinetic model for heterogeneous mammalian cell populations. III. Tritiated thymidine studies: correlations among multiple kinetic parameters in human tumors. J Theor Biol 1977;65: 421-464.
23. Shackney S. Interrelationships among the DNA content distribution, cell kinetics, and cell morphology: theoretical considerations. Experimental correlations, and clinical implications. In: Drewinko BaH, editor. Growth kinetics and biochemical regulation of normal and malignant cells. Baltimore: Williams & Wilkins; 1977. p 391-409.
24. Musgrove E, Seaman M, Hedley D. Relationship between cytoplasmic pH and proliferation during exponential growth and cellular quiescence. Exp Cell Res 1987;172:65-75.
25. Weinberg R. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
26. Jiang Z, Zacksenhaus E, Gallie B, Phillips R. The retinoblastoma gene family is differentially expressed during embryogenesis. Oncogene 1997;14:1789-1797.
27. Clarke A, Maandag E, van Roon M, van der Lugt N, van der Valk M, Hooper M, Berns A, Riele H. Requirement for a functional Rb-1 gene in murine development. Nature 1992;359:328-330.
28. Zacksenhaus E, Jiang Z, Chung D, Marth J, Phillips R, Gallie B. Rb controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. Genes Dev 1996;10: 3051-3064.
29. Howes K, Ransom N, Papermaster D, Lasudry J, Albert D, Windle J. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev 1994;8:1300-1310.
30. Wang J, Guo K, Wills K, Walsh K. Rb functions to inhibit apoptosis during myocyte differentiation. Cancer Res 1997;57:351-354.
31. Morgenbesser S, Williams B, Jacks T, DePinho R. p-53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994;371:72-74.
32. Ikeda M, Jakoi L, Nevins J. A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc Natl Acad Sci USA 1996;93:3215-3220.
33. Chen P-L, Scully P, Shew J-Y, Wang J, Lee W. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989;58:1193-1198.
34. 1 is dependent on growth status. Oncogene 1991;6:317-322.
35. Delia D, Goi K, Mizutani S, Yamada T, Aiello A, Fontanella E, Lamorte G, Iwata S, Ishioka C, Krajewski S, Reed J, Pierotti M. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 mutations. Oncogene 1997;14:2137-2147.
36. 1 during growth arrest. Exp Cell Res 1998;241:324-331.
37. Harvey M, Sands A, Weiss R, Hegi M, Wiseman R, Pantazis P, Giovanella B, Tainsky M, Bradley A. Donehower L. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993;8:2457-2467.
38. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower L. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 1995;9:305-311.
39. 1 progression in NIH 3T3 cells. Mol Cell Biol 1995;15:3645-3663.
40. Schlaepfer D, Hanks S, Hunter T, van de Geer P. Integrin-mediated signal transduction linked to ras pathway by GRB2 binding to focal adhesion kinase. Nature 1994;374:786-791.
41. Chen Q, Lin T, Der C, Juliano R. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras. J Biol Chem 1996;271:18122-18127.
42. King W, Mattaliano M, Chan T, Tsichlis P, Brugge J. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/ mitogen activated protein kinase pathway activation. Mol Cell Biol 1997;17:4406-4418.
43. Hara T, Miyajima A. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Stem Cells 1996;14:605-618.
44. shc, Raf-1, and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth responsive B cell line. J Immunol 1994;153:4436-4447.
45. Surmacz E, Reiss K, Sell C, Baserga R. Cyclin D1 messenger RNA is inducible by platelet-derived growth factor in cultured fibroblasts. Cancer Res 1992;52:4522-4525.
46. 1 checkpoint. Mol Cell Biol 1996;16:6917-6925.
47. Dufourny B, Alblas J, van Teeffelen H, van Schaik FM, van der Burg B, Steenbergh P, Sussenbach J. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997;272:31163-31171.
48. Haigler H, Ash J, Singer S, Cohen S. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci USA 1978;75:3317-3321.
49. 1 cyclins. Cell 1993;73:1059-1066.
50. Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272: 877-880.
51. LaBaer J, Garrett M, Stevenson L, Slingerland J, Sandhu C, Chou H, Fattaey A, Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11:847-862.
52. Waters C, Littlewood T, Hancock D, Moore J, Evan G. c-myc protein expression in untransformed fibroblasts. Oncogene 1991;6:101-109.
53. 1. Nature 1987;328:445-449.
54. Halevy O, Novitch B, Spicer D, Skapek S, Rhee J, Hannon G, Beach D, Lassar A. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018-1021.
55. 2 phases of the cell cycle. J Cell Biol 1996;135:441-456.
56. Wang J, Walsh K. Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-depcndent kinase 4 complex. Cell Growth Differ 1996;7: 1471-1478.
57. Rao S, Chu C, Kohtz D. Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol 1994;14:5259-5267.
58. Guo K, Walsh K. Inhibition of myogenesis by multiple cyclin-cdk complex. J Biol Chem 1997;272:791-797.
59. 1. Mol Cell Biol 1988;8:1614-1624.
60. Prochownik E, Kukowska J. Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation. Nature 1986; 322:848-849.
61. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984;312:646-649.
62. Finlay C, Hinds P, Tan T-H, Eliyahu D, Oren M, Levine A. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539.
63. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989;86:8763-8767.
64. Finlay C, Hinds P, Levine A. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-1093.
65. Hinds P, Finlay C, Levine A. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989;63:739-746.
66. Baker S, Markowitz S, Fearon E, Willosn J, Vogelstein B. Suppression of human colorectal carcinoma cell growth of wild-type p53. Science 1990;249:912-915.
67. Hirakawa T, Ruley H. Rescue of cells from ras oncogene-induced growth arrest by a second, complementing, oncogene. Proc Natl Acad Sci USA 1988;85:1519-1523.
68. Hicks G, Egan S, Greenberg A, Mowat M. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol Cell Biol 1991;11:1344-1352.
69. Bischoff F, Strong L, Yim S, Pratt D, Siciliano M, Giovanella B, Tainsky M. Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome. Oncogene 1991;6:183-186.
70. El-Deiry W, Harper J, O'Connor P, Velculescu V, Canman C, Jackman J, Pietenpol J, Burrell M, Hill D, Wang Y, Wiman K, Mercer W, Kastan M, Kohn K, Elledge S, Kinzler K, Vogelstein B. WAF1/CIPI is induced in p53-mediated, GI arrest and apoptosis. Cancer Res 1994;54:1169-1174.
71. Lloyd A, Obermuller F, Staddon S, Barth C, McMahon M, Land H. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev 1997;11:663-677.
72. Steinman R, Hoffman B, Iro A, Guillouf C, Liebermann D. Induction of p21WAF-1/CIP1B during differentiation. Oncogene 1994;9:3389-3396.
73. Michieli P, Chedid M, Lin D, Pierce J, Mercer W, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway, Cancer Res 1994;54: 3391-3395.
74. Polyak K, Waldman T, He T-C, Kinzler K, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996;10:1945-1952.
75. Li Y, Jenkins C, Nichols M, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994;9:2261-2268.
76. WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res 1996;56:31-35.
77. Hiyama H, Iavarone A, LaBaer J, Reeves S. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 without altering cell cycle progression. Oncogene 1997;14:2533-2542.
78. Harrington H, Bennett M, Fanidi A, Evan G. c-Myc induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 1994;13:3286-3295.
79. Canman C, Gilmer T, Coutts S, Kastan M. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995;9: 600-611.
80. waf1/cip1. Genes Dev 1994;8:2817-2830.
81. 1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995;92:8493-8497.
82. Moore J, Boswell S, Hoffman R, Burgess G, Hromas R. Mutant H-ras over-expression inhibits a random apoptotic nuclease in myeloid leukemia cells. Leuk Res 1993;17:703-709.
83. Lau Q, Brusselbach S. Muller R Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 1998;16:1899-1902
84. Weissinger E, Eissner G, Grammrr C, Fackler S, Haefner B, Yoon L, Lu K, Bazarov A, Sedivy J. Mischak H, Koleb W. Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells. Mol Cell Biol 1997;17:3229-3241.
85. Datta S, Dudeck H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg M. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.
86. Kulik G, Klippel A, Weber M. Antiapopiotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-1606.
87. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne P. Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositied 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997;16:2783-2793.
88. Kinoshita T, Yokota T, Arai K-I, Miyajima A. Regulation of Bcl-2 expression by oncogenic ras protein in hematopoietic cells. Oncogene 1995;10:2207-2212.
89. 1. Cell 1996;87:619-628.
90. Haldar S, Negrini M, Monne M, Sabbione S, Croce C. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-2097.
91. Sakamuro D, Eviner V, Elliott K, Showe L, White E. Prendergast G. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 1995;11:2411-2418.
92. Selvakumaran M, Lin H-K, Miyashita T, Wang H, Krajewski S, Reed J, Hoffman B, Liebermann D. Immediate early up-regulation of bax expression by p53 but not TGFβ1: a paradigm for distinct apoptotic pathways Oncogene 1994;9:1791-1798.
93. Hermeking H, Eick D. Mediation of c-myc-induced apoptosis by p53. Science 1994;265:2091-2093.
94. Qin X-Q, Livingston D, Kaelin WG Jr, Adams P. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994;91:10918-10922.
95. Hiebert S, Packham G, Strom D, Haffner R, Oren M, Zambetti G, Cleveland J. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 1995;15:6864-6874.
96. Reisman D, Elkind N, Roy B, Beamon J, Rotter V. c-Myc transactivates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 1993;4:57-65.
97. Askew D, Ashmun R, Simmins B, Cleveland J. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991;6:1915-1922.
98. Merlo G, Basolo F, Fiore L, Duboc L, Hynes N. p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J Cell Biol 1995;128: 1185-1196.
99. Pandey S, Wang E. Cells en route to apoptosis are characterized by the upregulation of c-fos, c-myc, c-jun, cdc2, and RB phosphorylation, resembling events of early cell-cycle traverse. J Cell Biochem 1995;58:135-150.
100. Askew D, Ihle J, Cleveland J. Activation of apoptosis associated with enforced myc expression in myeloid progenitor cells is dominant to the suppression of apoptosis by interleukin-3 or erythropoietin. Blood 1993;82:2079-2087.
101. Nevins J. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992;258:424-429.
102. Oswald F, Lovec H, Moroy T, Lipp M. E2F-dependent regulation of human MYC: transactivation by cyclins D1 and A overrides tumor suppressor protein functions. Oncogene 1994;9:2029-2036.
103. Jansen-Durr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G, Eilers M. Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci USA 1993;90:3685-3689.
104. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996;382:511-517.
105. DeGregori J, Kowalik T, Nevins J. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis - and G1/S-regulatory genes Mol Cell Biol 1995;15:4215-4224.
106. CDK2 is a component of the E2F-cyclin A complex. Cell 1992;68: 167-176.
107. Krude T, Jackman M, Pines J, Laskey R. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. Cell 1997;88:109-119.
108. Krek W, Ewen M, Shirodkar S, Arany Z, Kaelin W Jr, Livingston D. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably hound cyclin A-dependent protein kinase. Cell 1994;78:161-172.
109. Johnson D. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogcne 1995;11:1685-1692.
110. Kip1 Mol Cell Biol 1995;15:4347-4352.
111. Matsuoka M, Kato J-Y, Fisher R, Morgan D, Sherr C. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol 1994;14:7265-7275.
112. Johnson D, Schwarz J, Cress W, Nevins J. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-352.
113. Land H, Parada L, Weinberg R. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596-602.
114. Parada L, Land H, Weinberg R, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984;312:649-651.
115. Johnson D, Cress W, Jakoi L, Nevins J. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994;91:12823-12827.
116. Wyllie A, Rose K, Morris R, Steel C, Foster E. Spandidos D. Rodent fibroblast tumors expressing human myc and ras genes: growth, metastasis, and endogenous oncogene expression. Br J Cancer 1987;56:251-259.
117. Alexander W, Adams J, Cory S. Oncogene cooperation in lymphocyte transformation: malignant conversion of Emμ-myc transgenic pre-B cells in vitro is enhanced by v-H-ras or v-raf but not v-abl. Mol Cell Biol 1989;9:67-73.
118. Amundadottir L, Nass S, Bercham G, Johnson M, Dickson R. Cooperation of TGFα and c-myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene 1996;13:757-765.
119. Klileif S, DeGregori J, Yee C, Otterson G, Kaye F, Nevins J, Howley P. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996;93:4350-4354.
120. Reddy G, Tiarks C, Pang L, Wuu J, Hsieh C-C, Queensberry P. Cell cycle analysis and synchronization of pluripotent heamatopoietic progenitor stem cells. Blood 1997;90:2293-2299.
121. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994:57:353-361.
122. Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerulff A, Jansen-Durr P, Strauss M, Bartek J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 1994;125:625-638.
123. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-1679.
124. Shackney S, Shankey T. Common patterns of genetic evolution in human solid tumors Cytometry 1997;29:1-27.
125. INK4 in human cancer Proc Natl Acad Sci USA 1994;91:11045-11049.
126. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin A, Zeuthen J, Bartek J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-5483.
127. INK+ protein is restricted to the subset of lung cancer lines that retains wild type RB. Oncogene 1994;9:3375-3378.
128. Backway K, McCulloch E, Chow S, Hedley D. Relationship between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res 1997;57:2446-2451.
129. Li X, Traganos F, Melamed M, Darzynkiewicz Z. Single-step procedure for labeling DNA strand breaks with fluorescein- or BODIPY-conjugated deoxynucleotides: detection of apoptosis and bromode-oxyuridine incorporation. Cytometry 1995:20:172-180.
130. Shackney SE. Pollice AA, Smith C. Janocko L, Sweeney L, Brown K, Singh S, Gu L-P, Yakulis R, Lucke J. Intracellular co-expression of EGF receptor. Her-2/neu, and H-ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. Clin Cancer Res 1998;4: 913-928.